OBJECTIVE: The dipeptide J1 acts as a prodrug of melphalan with a significant increased potency in vitro resulting from activation by cellular aminopeptidases. The current study was performed to evaluate the ex vivo profile of J1 using 176 primary tumor cell cultures from patients. In addition, the activity of J1 in combination with eight standard drugs, representing different mechanistic classes, was studied in nine different human tumor cell lines of different histopathological origin. METHODS: Ex vivo evaluation of tumor type selectivity, was performed using the established fluorometric microculture cytotoxicity assay (FMCA). Combinations between J1 and eight standard chemotherapeutic drugs were analyzed using the median-effect method. RESULTS: The prodrug J1 expressed approximately 50- to 100-fold higher potency but similar activity profile as that of its metabolite, melphalan. The difference was greater in some diagnoses (e.g. breast cancer, NHL and AML), and exceptionally high in some breast cancer samples with aggressive phenotypes. Combination analysis of J1 and standard chemotherapeutics yielded several potentially additive and synergistic interactions, most striking for etoposide with significant synergism in all studied cell lines. CONCLUSIONS: In conclusion, the ex vivo profile suggests that further evaluation of J1 as the alkylating agent in for example aggressive breast cancer might be of particular interest, preferentially in combination with DNA-topoisomerase II inhibitors like etoposide.
OBJECTIVE: The dipeptide J1 acts as a prodrug of melphalan with a significant increased potency in vitro resulting from activation by cellular aminopeptidases. The current study was performed to evaluate the ex vivo profile of J1 using 176 primary tumor cell cultures from patients. In addition, the activity of J1 in combination with eight standard drugs, representing different mechanistic classes, was studied in nine different humantumor cell lines of different histopathological origin. METHODS: Ex vivo evaluation of tumor type selectivity, was performed using the established fluorometric microculture cytotoxicity assay (FMCA). Combinations between J1 and eight standard chemotherapeutic drugs were analyzed using the median-effect method. RESULTS: The prodrug J1 expressed approximately 50- to 100-fold higher potency but similar activity profile as that of its metabolite, melphalan. The difference was greater in some diagnoses (e.g. breast cancer, NHL and AML), and exceptionally high in some breast cancer samples with aggressive phenotypes. Combination analysis of J1 and standard chemotherapeutics yielded several potentially additive and synergistic interactions, most striking for etoposide with significant synergism in all studied cell lines. CONCLUSIONS: In conclusion, the ex vivo profile suggests that further evaluation of J1 as the alkylating agent in for example aggressive breast cancer might be of particular interest, preferentially in combination with DNA-topoisomerase II inhibitors like etoposide.
Authors: M L Donato; D M Gershenson; J T Wharton; C M Ippoliti; A S Aleman; D Bodurka-Bevers; M W Bevers; T W Burke; C F Levenback; J K Wolf; R S Freedman; R C Bast; J L Gajewski; R E Champlin Journal: Gynecol Oncol Date: 2001-09 Impact factor: 5.482
Authors: Adolfo Varona; Lorena Blanco; José I López; Javier Gil; Ekaitz Agirregoitia; Jon Irazusta; Gorka Larrinaga Journal: Am J Physiol Renal Physiol Date: 2006-09-19
Authors: A U Buzdar; S S Legha; G R Blumenschein; G N Hortobagyi; H Y Yap; F C Schell; B C Barnes; G Fraschini; G P Bodey Journal: Cancer Date: 1982-05-01 Impact factor: 6.860
Authors: T Demirer; V A Uysal; M Ayli; Y Genc; O Ilhan; H Koc; M Dagli; M Arat; N Gunel; T Fen; S Dincer; N Ustael; M Yildiz; T Ustun; E Seyrek; G Ozet; O Muftuoglu; H Akan Journal: Bone Marrow Transplant Date: 2003-05 Impact factor: 5.483
Authors: Karin Birkenkamp-Demtroder; Lise Lotte Christensen; Sanne Harder Olesen; Casper M Frederiksen; Päivi Laiho; Lauri A Aaltonen; Søren Laurberg; Flemming B Sørensen; Rikke Hagemann; Torben F ØRntoft Journal: Cancer Res Date: 2002-08-01 Impact factor: 12.701
Authors: Åke Berglund; Anders Ullén; Alla Lisyanskaya; Sergey Orlov; Hans Hagberg; Bengt Tholander; Rolf Lewensohn; Peter Nygren; Jack Spira; Johan Harmenberg; Markus Jerling; Carina Alvfors; Magnus Ringbom; Eva Nordström; Karin Söderlind; Joachim Gullbo Journal: Invest New Drugs Date: 2015-11-10 Impact factor: 3.850
Authors: Alexander Schepsky; Gunnhildur Asta Traustadottir; Jon Petur Joelsson; Saevar Ingthorsson; Jennifer Kricker; Jon Thor Bergthorsson; Arni Asbjarnarson; Thorkell Gudjonsson; Nina Nupponen; Ana Slipicevic; Fredrik Lehmann; Thorarinn Gudjonsson Journal: Cancer Med Date: 2020-07-27 Impact factor: 4.452
Authors: Paul G Richardson; Albert Oriol; Alessandra Larocca; Joan Bladé; Michele Cavo; Paula Rodriguez-Otero; Xavier Leleu; Omar Nadeem; John W Hiemenz; Hani Hassoun; Cyrille Touzeau; Adrián Alegre; Agne Paner; Christopher Maisel; Amitabha Mazumder; Anastasios Raptis; Jan S Moreb; Kenneth C Anderson; Jacob P Laubach; Sara Thuresson; Marcus Thuresson; Catriona Byrne; Johan Harmenberg; Nicolaas A Bakker; María-Victoria Mateos Journal: J Clin Oncol Date: 2020-12-09 Impact factor: 44.544
Authors: Charlotte Carlier; Sara Strese; Kristina Viktorsson; Ebba Velander; Peter Nygren; Maria Uustalu; Therese Juntti; Rolf Lewensohn; Rolf Larsson; Jack Spira; Elly De Vlieghere; Wim P Ceelen; Joachim Gullbo Journal: Oncotarget Date: 2016-09-13
Authors: Malin Wickström; Peter Nygren; Rolf Larsson; Johan Harmenberg; Jakob Lindberg; Per Sjöberg; Markus Jerling; Fredrik Lehmann; Paul Richardson; Kenneth Anderson; Dharminder Chauhan; Joachim Gullbo Journal: Oncotarget Date: 2017-06-08